We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Is Expanded Mutation Testing Practical for CF Carrier Screening?

By LabMedica International staff writers
Posted on 06 Dec 2010
A new study questioned the value of expanded genetic testing for cystic fibrosis.

The findings suggested that expanded panels might promote ill-informed decisions and anxiety for physicians and couples seeking testing to determine their risk of passing the disease to their children.

Testing for genetic mutations beyond those medically recommended is unlikely to prevent the birth of children with classic cystic fibrosis and may detect mutations causing only mild disease, according to an eight-year study performed by scientists at Quest Diagnostics (Madison, NJ, USA). More...


Participants in the study came from an ethnically diverse American population. It involved analyses of more than three million deidentified test results performed by the company's laboratories over an eight-year period ending in April 2010.

The company's scientists found that CF testing, using 23 recommended mutations plus an additional eight to nine clinically validated mutations performed for patients in its labs, identified nearly 100 % of carriers among Caucasians, including Ashkenazi Jews, the highest risk group for CF, as compared to well-established estimated carrier rates. The CF testing also performed comparably to the American College of Obstetricians and Gynecologists (ACOG; Washington DC, USA) predictions for performance in detecting carriers in African, Hispanic, and Asian Americans.

In 2004, the American College of Medical Genetics (ACMG; Bethesda, MD, USA) and ACOG recommended physicians offer panels based on the 23 recommended mutations to couples to help identify carrier status. Despite the guidelines, expanded test panels that identify dozens up to nearly 100 nonguideline recommended mutations are widely offered by certain laboratories in the US.

The study findings appear online in the journal Genetics in Medicine.

"This outstanding study should finally put to rest the continuing debates and misinformation that suggest more mutations are always better when it comes to cystic fibrosis carrier screening," said Wayne W. Grody, MD, PhD, professor in the departments of pathology and laboratory medicine, pediatrics, and Human Genetics at the UCLA School of Medicine (Los Angeles, CA, USA). Dr. Grody led one of the influential NIH-funded pilot studies on CF carrier screening and cochaired the ACMG committee that developed the recommended core mutation-screening panel. He is not affiliated with the study or with Quest Diagnostics.

Related Links:
Quest Diagnostics
American College of Obstetricians and Gynecologists
American College of Medical Genetics
UCLA School of Medicine


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
New
MR-proADM Test
B•R•A•H•M•S MR-proADM KRYPTOR test
Japanese Encephalitis Test
Japanese Encephalitis Virus Real Time PCR Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: A large, international study led by City of Hope found that the new, investigational liquid biopsy, called PANXEON, was highly sensitive in detecting stage 1 and 2 pancreatic cancer and had a low rate of false positives. The test was also able to identify high-grade dysplasia, a precancerous condition of the pancreas, potentially enabling intervention before cancer develops. (Photo courtesy of City of Hope)

Multi-Biomarker Blood Test Shows Promise for Early Pancreatic Cancer Detection

Pancreatic cancer has the lowest survival rates of any cancer, with only 14% of patients alive five years after diagnosis. The disease is typically discovered after it has spread, and an estimated 90%... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Technology

view channel
Image: Graphical Abstract (Wenjie Zhang, Zeyu Luo, Kaijie Liu, et al. Science Bulletin, 2026. doi:10.1016/j.scib.2026.09.016)

Multimodal AI Framework Aims to Guide Cancer Immunotherapy Decisions

Cancer immunotherapy has reshaped oncology, but heterogeneous responses and immune-related toxicities continue to complicate routine decision-making. Standard biomarkers, including programmed death-ligand... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.